Moderna set to enter into a long term agreement with the Government of Mexico

Moderna has recently announced that they have signed a Memorandum of Understanding for a long-term strategic agreement with the Mexican Government, Laboratorios de Biológicos y Reactivos de Mexico, and Laboratorios Liomont, to enhance Mexico’s health sovereignty and mRNA manufacturing resilience. This 5 year agreement will include the supply of Moderna’s respiratory vaccine portfolio, as well as technology transfer to Liomont, a Mexican pharmaceutical company with state-of-the-art manufacturing facilities, to produce mRNA-1273, Moderna’s COVID-19 vaccine, and establish a reliable in-country supply of respiratory vaccines.

“We are proud to support Mexico in its mission to strengthen national health security,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Through this agreement, we will be able to provide the Mexican people with access to our respiratory vaccines and critical pandemic response capacity. This collaboration also reflects the growing demand for these vaccines in Mexico, and we are excited about the opportunity to support public health needs while driving sales growth through geographic diversification.”

Note that this agreement follows the recent Federal Commission for the Protection against Sanitary Risk approval of Moderna’s 2025-2026 COVID-19 vaccine for individuals aged 6 months and older, as well as the purchase adjudication with the Government of Mexico for the supply of up to 10 million doses of Moderna’s 2025-2026 COVID-19 vaccine to Logística y Transporte para la Industria de la Salud, S.A.P.I. de C.V.

---

---

Related Topics and Keywords

Mexico, Moderna